Division of Clinical Epidemiology & Aging Research, German Cancer Research Center, Heidelberg, Germany.
Oncologist. 2011;16(11):1600-3. doi: 10.1634/theoncologist.2011-0229. Epub 2011 Oct 3.
Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients.
Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998-2002 to 2003-2007.
The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998-2002 to 40.3% and 20.8%, respectively, in 2003-2007. The greatest improvements were observed for patients aged 15-44 years, with 5- and 10-year RSRs reaching >70% and ~50%, respectively, but improvements were also seen for patients aged >70 years.
Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.
过去几年,多发性骨髓瘤的治疗发生了重大变化,临床试验报告使用新药物可获得更高的生存结果。先前的研究表明,骨髓瘤年轻患者的生存率有所提高,但老年患者则不然。在此,我们更新了 21 世纪初骨髓瘤患者的生存估计,以确定在人群水平上是否可以继续看到持续的改善,以及这种改善是否已经扩展到老年患者。
我们使用时期分析方法,检查来自监测、流行病学和最终结果数据库的数据,估计 1998-2002 年至 2003-2007 年期间 5 年和 10 年相对生存率(RSR)的变化。
多发性骨髓瘤患者的 5 年和 10 年 RSR 总体上均有所提高,从 1998-2002 年的 32.8%和 15%分别提高到 2003-2007 年的 40.3%和 20.8%。年龄在 15-44 岁的患者的改善最为显著,5 年和 10 年 RSR 分别达到>70%和~50%,但年龄>70 岁的患者也有改善。
总体而言,多发性骨髓瘤患者的生存持续改善,包括老年患者,这表明新的治疗选择继续对人群产生影响。